Loading the records…
Loading the records…
SEC Form 4 documents direct changes in beneficial ownership of securities for public corporations. The reporting insider, Lucidi Bruno, holds the title of Director at Atea Pharmaceuticals, Inc..
On 2026-11-19, the insider transacted 104,360 shares.The shares were transacted at a weighted average price of $2.01 per share, resulting in a total market-relevant value of $209K.
Lucidi Bruno (Director) sold $209K of $AVIR
Verify the accuracy of this insider transaction and corporate entity independently. HillSignal pulls data directly from official SEC databases; use the sources below to corroborate.